Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors

Yang, Juan; Pearl, Michelle; DeLorenze, Gerald N.; Romero, Roberto; Dong, Zhong; Jelliffe‐Pawlowski, Laura L.; Currier, Robert; Flessel, Monica; Kharrazi, Martin

doi:10.1016/j.ajog.2016.04.002

Cited by 29 publications

(20 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the breadth of data demonstrating common pathophysiological underpinning across spontaneous and provider initiated subtypes of PTB including among those ± preeclampsia [ 23 – 28 ], it appears possible that a predictive test could be developed that covers a wider range of PTB phenotoypes. For example, all PTB subtypes ± preeclampsia have been shown to have strong links to markers of immune function (e.g., cytokines and chemokines) [ 23 – 26 ] and to angiogenic growth factors (e.g., vascular endothelial growth factor (VEGF)) [ 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

Prediction of preterm birth with and without preeclampsia using mid-pregnancy immune and growth-related molecular factors and maternal characteristics

et al. 2018

View full text Add to dashboard Cite

Objective:To evaluate if mid-pregnancy immune and growth-related molecular factors predict preterm birth (PTB) with and without (±) preeclampsia.Study design:Included were 400 women with singleton deliveries in California in 2009–2010 (200 PTB and 200 term) divided into training and testing samples at a 2:1 ratio. Sixty-three markers were tested in 15–20 serum samples using multiplex technology. Linear discriminate analysis was used to create a discriminate function. Model performance was assessed using area under the receiver operating characteristic curve (AUC).Results:Twenty-five serum biomarkers along with maternal age <34 years and poverty status identified >80% of women with PTB ± preeclampsia with best performance in women with preterm preeclampsia (AUC = 0.889, 95% confidence interval (0.822–0.959) training; 0.883 (0.804–0.963) testing).Conclusion:Together with maternal age and poverty status, mid-pregnancy immune and growth factors reliably identified most women who went on to have a PTB ± preeclampsia.

show abstract

Section: Introductionmentioning

confidence: 99%

Prediction of preterm birth with and without preeclampsia using mid-pregnancy immune and growth-related molecular factors and maternal characteristics

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The magnitude of change of Placental growth factor (PlGF) was 14.5 fold, and this protein plays an important role in the control of angiogenesis, which is a key process in placental development. Low concentrations of PlGF have already been reported in patients who subsequently developed early onset preeclampsia(104-107, [234][235][236][237], fetal death of unknown origin(111, 112), small-for-gestational-age infants (with and without Doppler abnormalities) (104-107), maternal floor infarction(109, 238, 239), mirror syndrome(114, 123, [240][241][242][243][244], and some forms of twin-to-twin transfusion syndrome (74). The identification of PlGF as a protein that undergoes dramatic changes in maternal plasma concentration in this study (and using current technologies) is reassuring, given its physiologic importance, as well as the prognostic value in measuring this concentration in maternal plasma to identify patients at risk for adverse pregnancy outcome.…”

Section: Meaning Of the Studymentioning

confidence: 96%

The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study

Romero

Erez

Maymon

et al. 2017

American Journal of Obstetrics and Gynecology

Self Cite

View full text Add to dashboard Cite

Objective Pregnancy is accompanied by dramatic physiologic changes in maternal plasma proteins. Characterization of the maternal plasma proteome in normal pregnancy is an essential step for understanding changes to predict pregnancy outcome. The objective of this study was to describe maternal plasma proteins that change in abundance with advancing gestational age, and determine biological processes that are perturbed in normal pregnancy. Materials and methods A longitudinal study included 43 normal pregnancies that had a term delivery of an infant who was appropriate for gestational age (AGA) without maternal or neonatal complications. For each pregnancy, 3 to 6 maternal plasma samples (median=5,) were profiled to measure the abundance of 1,125 proteins using multiplex assays. Linear mixed effects models with polynomial splines were used to model protein abundance as a function of gestational age, and significance of the association was inferred via likelihood ratio tests. Proteins considered to be significantly changed were defined as having: 1) more than 1.5 fold change between 8 and 40 weeks of gestation; and 2) a false discovery rate (FDR) adjusted p-value <0.1. Gene ontology enrichment analysis was employed to identify biological processes over-represented among the proteins that changed with advancing gestation. Results 1) Ten percent (112/1,125) of the profiled proteins changed in abundance as a function of gestational age; 2) of the 1,125 proteins analyzed Glypican-3, sialic acid-binding immunoglobulin-type lectins (Siglec)-6, placental growth factor (PlGF), C-C motif (CCL)-28, carbonic anhydrase 6, Prolactin (PRL), interleukin-1 receptor 4 (IL-1 R4), dual specificity mitogen-activated protein kinase 4 (MP2K4) and pregnancy-associated plasma protein-A (PAPP-A) had more than 5 fold change in abundance across gestation. These 9 proteins are known to be involved in a wide range of both physiologic and pathologic processes, such as growth regulation, embryogenesis, angiogenesis immunoregulation, inflammation etc.; and 3) biological processes associated with protein changes in normal pregnancy included defense response, defense response to bacteria, proteolysis and leukocyte migration (FDR=10%). Conclusions The plasma proteome of normal pregnancy demonstrates dramatic changes in both magnitude of changes and the fraction of the proteins involved. Such information is important to understand the physiology of pregnancy, development of biomarkers to differentiate normal vs. abnormal pregnancy, and determine the response to interventions.

show abstract

“…Black women had the highest levels of PIGF relative to white and hispanic women, whereas the concentration of sEng was highest among hispanic women. PIGF and sEng were least associated with early‐onset pre‐eclampsia among black women . Therefore, estimation of the levels of angiogenic biomarkers in different clinical settings is strongly recommended to ascertain population reference values.…”

Section: Circulating Levels Of Angiogenic Factors During Pregnancymentioning

confidence: 99%

Role of angiogenic factors in the pathogenesis and management of pre‐eclampsia

Ngene

Moodley

2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

The cause of pre-eclampsia is unknown. Different postulates have been developed to explain its pathogenesis. The two-stage theory and angiogenic imbalance are two notable postulates of the disease. Together, they propose that there is a lack of cytotrophoblastic invasion of the uterine spiral arteries in pre-eclampsia. The lumen of these arteries remains narrow instead of converting to the wide channels seen in normal pregnancy, and result in poor placental perfusion. Coupled with maternal susceptibility, this process leads to the release of mediators, including an excess of anti-angiogenic factors that result in the clinical manifestations of the disease. Circulating levels of anti-angiogenic factors such as soluble fms-like tyrosine kinase-1 increase, whereas pro-angiogenic factors such as placental growth factor decrease. Assessment of the circulating concentrations of these angiogenic factors, such as the soluble fms-like tyrosine kinase-1/placental growth factor ratio, has diverse clinical relevance in pre-eclampsia. The present review describes the role of angiogenic factors in the pathogenesis and management of pre-eclampsia.

show abstract

Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors

Cited by 29 publications

References 49 publications

Prediction of preterm birth with and without preeclampsia using mid-pregnancy immune and growth-related molecular factors and maternal characteristics

Prediction of preterm birth with and without preeclampsia using mid-pregnancy immune and growth-related molecular factors and maternal characteristics

The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study

Role of angiogenic factors in the pathogenesis and management of pre‐eclampsia

Contact Info

Product

Resources

About